Related Experiment Videos
Toxicity of the alkylating agent bendamustin
Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement
|January 1, 1985
Summary
Bendamustine toxicity was assessed in rats and mice, revealing bone marrow, kidney, intestine, and lymphatic system as primary targets. This study provides a basis for comparing Bendamustine
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Bendamustine is an alkylating agent used in cancer therapy.
- Understanding its toxicity profile is crucial for safe clinical application.
- Chlorambucil serves as a reference compound for comparative toxicity assessment.
Purpose of the Study:
- To determine the acute toxicity (MTD, LD50, LD100) of Bendamustine in rats and mice via intravenous and oral routes.
- To conduct a 28-day oral subchronic toxicity study of Bendamustine in male rats, comparing it with Chlorambucil.
- To evaluate the toxicological effects and identify target organs for both Bendamustine and Chlorambucil.
Main Methods:
- Acute toxicity studies involving determination of maximum tolerated dose (MTD), LD50, and LD100.
- A 28-day oral subchronic study in male rats with Bendamustine (5-40 mg/kg/day) and Chlorambucil (1-10 mg/kg/day).
- Evaluation of body weight, food/water intake, hematology, clinical chemistry, and histopathology.
Main Results:
- Bendamustine and Chlorambucil share common target organs: bone marrow, kidney, intestine, and lymphatic system.
- Differences in toxicity were observed quantitatively between the two agents.
- Chlorambucil exhibited specific toxicity, including testicular atrophy and pancreatic effects at 5 mg/kg/day.
Conclusions:
- The toxicological data provide a foundation for evaluating the therapeutic range of orally administered Bendamustine relative to Chlorambucil.
- Bendamustine demonstrates a distinct toxicity profile compared to Chlorambucil.
- Further studies are warranted to fully elucidate the therapeutic window and safety of Bendamustine.